Market cap
$12 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | 21.34 | 58.55 | 21.20 | 6.15 |
| Net Profit | -7.79 | 15.43 | 39.20 | 18.93 | -0.53 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Jun-24 | Jun-23 |
| EBIT-Margin
| -- | -- | -7,150.00 | -- | -- |
| Net Margin
| -- | -- | -10,346.05 | -- | -- |
| Return on equity
| -271.63 | -485.58 | -162.48 | -378.83 | -233.90 |
| Return on Capital
| -271.63 | -485.58 | -- | -378.83 | -233.90 |
| Return on Assets
| -155.81 | -244.46 | -95.06 | -167.00 | -147.03 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
-378.83
|
-233.90
|
-202.17
|
-706.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-162.48
Lower than Peers by 122.08
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
-162.48
|
-378.83
|
-233.90
|
-202.17
|
-706.81
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-95.06
Lower than Peers by 64.08
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
-95.06
|
-167.00
|
-147.03
|
-153.40
|
-465.07
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-7,150.00
Lower than Peers by 7,066.38
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
-7,150.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-10,346.05
Lower than Peers by 10,253.38
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
-10,346.05
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.26
Lower than Peers by 0.26
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
-0.26
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
EBIT Growth
58.55
Higher than Peers by 59.35
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
58.55
|
42.88
|
34.77
|
40.59
|
-438.63
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
39.20
Higher than Peers by 46.50
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
39.20
|
41.97
|
35.24
|
40.98
|
-279.17
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.45
Lower than Peers by 3.36
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
2.45
|
2.45
|
1.06
|
3.32
|
4.24
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.45
Lower than Peers by 3.25
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
2.45
|
--
|
0.93
|
3.69
|
4.51
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
--
|
--
|
-1,620.14
|
-1,468.38
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
0.01
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
2,755.98
|
-3,235.51
|
-6,799.74
|
-3,779.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
16,572.39
|
18,423.82
|
16,704.10
|
24,141.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
7.81
Higher than Peers by 2.63
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
7.81
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.37
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
-1.37
|
0.58
|
0.10
|
0.52
|
0.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
12
Lower than Peers by 134
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
|
12
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|